We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > foralumab

News List

Tiziana and FHI Clinical work on Phase II intranasal Covid-19 drug trial pharmaceutical-technology
June 25, 2021
Tiziana Life Sciences has entered an agreement with FHI Clinical to carry out a Phase II proof-of-concept clinical trial of intranasal Foralumab in severe Covid-19 patients hospitalised with pulmonary inflammation in Brazil.
Tiziana to commence trial of nasal Covid-19 monoclonal antibody pharmaceutical-technology
March 31, 2021
Tiziana Life Sciences is set to commence a Phase II trial of its nasal anti-CD3 human monoclonal antibody (mAb), Foralumab, in moderate to severe hospitalised Covid-19 patients in Brazil.
Tiziana’s Foralumab suppresses lung inflammation in Brazil Covid-19 trial pharmaceutical-technology
February 04, 2021
Tiziana Life Sciences has reported positive data from an exploratory clinical study in Brazil evaluating its nasally administered anti-CD3 human monoclonal antibody, Foralumab, in Covid-19 patients.
Tiziana submits IND for Foralumab oral formulation in NASH pharmatimes
March 27, 2019
Tiziana Life Sciences has announced the submission of an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for an oral formulation of Foralumab, used for the treatment of autoimmune and inflammatory diseases such as n